Precision BioSciences Announces Phase 1 ELIMINATE-B Cohort 1 Safety And Efficacy At 0.2 Mg/Kg With 47ā69% HBsAg Reduction, Durable 50% Response At 7 Months, Sulkowski Named Head Clinical Development Advisor And Cash Runway Extended To H2 2027
Author: Benzinga Newsdesk | August 06, 2025 07:16am